Multiple sulfatase deficiency

Last reviewed

🖨 Print for my doctorAdvocacy Hub →
ORPHA:585OMIM:272200E75.2
Who is this for?
Show terms as
1Active trials1Specialists8Treatment centers

Where are you in your journey?

UniteRare data is sourced from FDA.gov, ClinicalTrials.gov, Orphanet, OMIM, and NORD.
Report missing data

Overview

Multiple sulfatase deficiency (MSD), also known as Austin disease or mucosulfatidosis, is an ultra-rare inherited lysosomal storage disorder caused by mutations in the SUMF1 gene (also called FGE gene), which encodes the formylglycine-generating enzyme. This enzyme is essential for the post-translational activation of all sulfatase enzymes in the body. When it is deficient, all known sulfatases (at least 17 in humans) are simultaneously impaired, leading to the accumulation of sulfated substrates including sulfatides, mucopolysaccharides (glycosaminoglycans), and steroid sulfates in multiple tissues and organs. The clinical presentation of MSD combines features of several individual sulfatase deficiency disorders, including metachromatic leukodystrophy, multiple mucopolysaccharidoses, and X-linked ichthyosis. Key features include progressive neurological deterioration with developmental delay and regression, leukodystrophy, coarse facial features, skeletal abnormalities (dysostosis multiplex), hepatosplenomegaly, ichthyosis (dry, scaly skin), and hearing loss. Three clinical subtypes have been described based on age of onset and severity: a severe neonatal form, a late-infantile form (most common), and a rare juvenile form. The late-infantile form typically presents between ages one and four years with developmental regression and progressive neurological decline. There is currently no cure or disease-specific treatment for multiple sulfatase deficiency. Management is supportive and symptomatic, addressing seizures, respiratory complications, nutritional needs, and physical rehabilitation. Enzyme replacement therapy and gene therapy approaches are under investigation but remain experimental. Prognosis is generally poor, particularly in the neonatal and late-infantile forms, with most severely affected individuals surviving into childhood or early adolescence. Genetic counseling is recommended for affected families.

Also known as:

Clinical phenotype terms— hover any for plain English:

Inheritance

Autosomal recessive

Passed on when both parents carry the same gene change; often skips generations

Age of Onset

Variable

Can begin at different ages, from infancy through adulthood

Orphanet ↗OMIM ↗NORD ↗

FDA & Trial Timeline

3 events
Jun 2023Safety and Efficacy of SMART101 in Adult Patients With Hematological Malignancies After Haploidentical HSCT With Post-transplant Cyclophosphamide

Smart Immune SAS — PHASE1, PHASE2

TrialRECRUITING
Oct 2020The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

PMV Pharmaceuticals, Inc — PHASE1, PHASE2

TrialRECRUITING
Dec 2017MPS (RaDiCo Cohort) (RaDiCo-MPS)

Institut National de la Santé Et de la Recherche Médicale, France

TrialRECRUITING

Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Treatments

No FDA-approved treatments are currently listed for Multiple sulfatase deficiency.

1 clinical trialare actively recruiting — trials can provide access to cutting-edge therapies.

View clinical trials →

Clinical Trials

1 recruitingView all trials with filters →
Other1 trial
MPS (RaDiCo Cohort) (RaDiCo-MPS)
Actively Recruiting
PI: Thierry BILLETTE DE VILLEMEUR (INSERM UMR 1141) · Sites: Angers; Bordeaux +21 more

Specialists

1 foundView all specialists →
AM
Adeline Vanderver, MD
Los Angeles, California
Specialist

Rare Disease Specialist

PI on 4 active trials1 Multiple sulfatase deficiency publication

Treatment Centers

8 centers
🏥 NORD

Baylor College of Medicine Rare Disease Center

Baylor College of Medicine

📍 Houston, TX

🏥 NORD

Stanford Medicine Rare Disease Center

Stanford Medicine

📍 Stanford, CA

🔬 UDN

NIH Clinical Center Undiagnosed Diseases Program

National Institutes of Health

📍 Bethesda, MD

🔬 UDN

UCLA UDN Clinical Site

UCLA Health

📍 Los Angeles, CA

🔬 UDN

Baylor College of Medicine UDN Clinical Site

Baylor College of Medicine

📍 Houston, TX

🔬 UDN

Harvard/MGH UDN Clinical Site

Massachusetts General Hospital

📍 Boston, MA

🏥 NORD

Mayo Clinic Center for Individualized Medicine

Mayo Clinic

📍 Rochester, MN

👤 Mayo Clinic Center for Individualized Medicine

🏥 NORD

UCLA Rare Disease Day Program

UCLA Health

📍 Los Angeles, CA

Travel Grants

No travel grants are currently matched to Multiple sulfatase deficiency.

Search all travel grants →NORD Financial Assistance ↗

Community

Open Multiple sulfatase deficiencyForum →

No community posts yet. Be the first to share your experience with Multiple sulfatase deficiency.

Start the conversation →

Latest news about Multiple sulfatase deficiency

Disease timeline:

New recruiting trial: A Prospective, Open-label, Randomized Controlled, Multicenter Clinical Study of MSD-HSCT Using a TBI or TMLI Conditioning Regimen for Adult ALL

A new clinical trial is recruiting patients for Multiple sulfatase deficiency

New recruiting trial: The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

A new clinical trial is recruiting patients for Multiple sulfatase deficiency

New recruiting trial: PTCy and ATG for MSD and MUD Transplants

A new clinical trial is recruiting patients for Multiple sulfatase deficiency

New recruiting trial: Sickle Cell Disease Transplant Using a Nonmyeloablative Approach for Patients With Anti-donor Red Cell Antibody

A new clinical trial is recruiting patients for Multiple sulfatase deficiency

New recruiting trial: MPS (RaDiCo Cohort) (RaDiCo-MPS)

A new clinical trial is recruiting patients for Multiple sulfatase deficiency

New recruiting trial: Safety and Efficacy of SMART101 in Adult Patients With Hematological Malignancies After Haploidentical HSCT With Post-transplant Cyclophosphamide

A new clinical trial is recruiting patients for Multiple sulfatase deficiency

Caregiver Resources

NORD Caregiver Resources

Support, advocacy, and financial assistance for caregivers of rare disease patients.

Mental Health Support

Rare disease caregiving can be isolating. Connect with counseling and peer support.

Family & Caregiver Grants

Financial assistance programs specifically for caregivers of rare disease patients.

Social Security Disability

Learn how rare disease patients may qualify for SSDI/SSI benefits.

Common questions about Multiple sulfatase deficiency

What is Multiple sulfatase deficiency?

Multiple sulfatase deficiency (MSD), also known as Austin disease or mucosulfatidosis, is an ultra-rare inherited lysosomal storage disorder caused by mutations in the SUMF1 gene (also called FGE gene), which encodes the formylglycine-generating enzyme. This enzyme is essential for the post-translational activation of all sulfatase enzymes in the body. When it is deficient, all known sulfatases (at least 17 in humans) are simultaneously impaired, leading to the accumulation of sulfated substrates including sulfatides, mucopolysaccharides (glycosaminoglycans), and steroid sulfates in multiple t

How is Multiple sulfatase deficiency inherited?

Multiple sulfatase deficiency follows a autosomal recessive inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.

Are there clinical trials for Multiple sulfatase deficiency?

Yes — 1 recruiting clinical trial is currently listed for Multiple sulfatase deficiency on UniteRare. See the clinical trials section on this page for phase, sponsor, and site details sourced from ClinicalTrials.gov.

Which specialists treat Multiple sulfatase deficiency?

1 specialists and care centers treating Multiple sulfatase deficiency are listed on UniteRare, sourced from ClinicalTrials.gov principal investigators, published research, and the NPPES NPI registry.